Northeast Regional Epilepsy Group (NEREG) - Hackensack — Hackensack, New Jersey

Northeast Regional Epilepsy Group (NEREG) - Hackensack is a clinical research site located in Hackensack, New Jersey, United States 07601.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Northeast Regional Epilepsy Group (NEREG) - Hackensack has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: GRIN-related Neurodevelopmental Disorder.

Sponsors: GRIN Therapeutics, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Hackensack

Browse all research sites in New Jersey · View every site in Hackensack

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Northeast Regional Epilepsy Group (NEREG) - Hackensack?

Northeast Regional Epilepsy Group (NEREG) - Hackensack has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Northeast Regional Epilepsy Group (NEREG) - Hackensack conducted?

Northeast Regional Epilepsy Group (NEREG) - Hackensack has 1 clinical trials on record, with 1 currently active. Their work covers GRIN-related Neurodevelopmental Disorder.

Is Northeast Regional Epilepsy Group (NEREG) - Hackensack accredited by Crixeo Clinical Trials?

Northeast Regional Epilepsy Group (NEREG) - Hackensack has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Northeast Regional Epilepsy Group (NEREG) - Hackensack?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.